CR20240216A - Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno - Google Patents
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastornoInfo
- Publication number
- CR20240216A CR20240216A CR20240216A CR20240216A CR20240216A CR 20240216 A CR20240216 A CR 20240216A CR 20240216 A CR20240216 A CR 20240216A CR 20240216 A CR20240216 A CR 20240216A CR 20240216 A CR20240216 A CR 20240216A
- Authority
- CR
- Costa Rica
- Prior art keywords
- disorder
- disease
- treatment
- sup
- naphthyridinone derivatives
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical class C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163282492P | 2021-11-23 | 2021-11-23 | |
| CN2022128601 | 2022-10-31 | ||
| PCT/IB2022/061218 WO2023094965A1 (en) | 2021-11-23 | 2022-11-21 | Naphthyridinone derivatives for the treatment of a disease or disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20240216A true CR20240216A (es) | 2024-07-01 |
Family
ID=84370237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20240216A CR20240216A (es) | 2021-11-23 | 2022-11-21 | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12084442B2 (enExample) |
| EP (2) | EP4436662B1 (enExample) |
| JP (1) | JP7826477B2 (enExample) |
| KR (1) | KR20240110040A (enExample) |
| CN (1) | CN118382623A (enExample) |
| AR (1) | AR127698A1 (enExample) |
| AU (1) | AU2022396087A1 (enExample) |
| CA (1) | CA3235682A1 (enExample) |
| CL (1) | CL2024001524A1 (enExample) |
| CO (1) | CO2024006398A2 (enExample) |
| CR (1) | CR20240216A (enExample) |
| DK (1) | DK4436662T3 (enExample) |
| DO (1) | DOP2024000096A (enExample) |
| EC (1) | ECSP24038829A (enExample) |
| ES (1) | ES3054973T3 (enExample) |
| FI (1) | FI4436662T3 (enExample) |
| HR (1) | HRP20251558T1 (enExample) |
| IL (1) | IL312689A (enExample) |
| JO (1) | JOP20240119A1 (enExample) |
| LT (1) | LT4436662T (enExample) |
| MA (1) | MA67325B1 (enExample) |
| MX (1) | MX2024006176A (enExample) |
| PE (1) | PE20241328A1 (enExample) |
| PL (1) | PL4436662T3 (enExample) |
| PT (1) | PT4436662T (enExample) |
| RS (1) | RS67492B9 (enExample) |
| TW (1) | TW202329949A (enExample) |
| UY (1) | UY40025A (enExample) |
| WO (1) | WO2023094965A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260015867A (ko) * | 2023-05-24 | 2026-02-03 | 노파르티스 아게 | 질환 또는 장애 치료용 나프티리디논 유도체 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA92121A (en) | 1904-11-07 | 1905-03-14 | William Waid Paddock | Pressure filter |
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| WO1993011782A1 (en) | 1991-12-19 | 1993-06-24 | Southwest Foundation For Biomedical Research | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6683113B2 (en) | 1999-09-23 | 2004-01-27 | Pharmacia Corporation | (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
| HUP0301335A3 (en) | 2000-04-12 | 2006-02-28 | Novartis Ag | Combination of organic compounds |
| DK1537114T3 (da) | 2002-08-07 | 2006-11-13 | Novartis Ag | Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande |
| CN100447142C (zh) | 2002-11-18 | 2008-12-31 | 诺瓦提斯公司 | 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法 |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| JP2007530550A (ja) | 2004-03-26 | 2007-11-01 | イーライ リリー アンド カンパニー | 異脂肪血症を治療するための化合物および方法 |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| JP5179174B2 (ja) | 2004-05-28 | 2013-04-10 | ノバルティス ファーマ アーゲー | アルドステロンシンターゼ阻害剤としてのテトラヒドロ−イミダゾ［１，５−ａ］ピリジン誘導体 |
| US7612088B2 (en) | 2004-05-28 | 2009-11-03 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
| CA2568164A1 (en) | 2004-05-28 | 2005-12-15 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
| WO2006005726A2 (en) | 2004-07-09 | 2006-01-19 | Speedel Experimenta Ag | Heterocyclic compounds |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| TW200804378A (en) | 2005-12-09 | 2008-01-16 | Speedel Experimenta Ag | Organic compounds |
| US20090156875A1 (en) | 2006-04-04 | 2009-06-18 | Takafumi Tomioka | Methane separation method, methane separation apparatus, and methane utilization system |
| TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| CA2660701A1 (en) | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
| EA200900811A1 (ru) | 2006-12-18 | 2009-12-30 | Новартис Аг | Имидазолы в качестве ингибиторов альдостеронсинтазы |
| KR20090090395A (ko) | 2006-12-18 | 2009-08-25 | 노파르티스 아게 | 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도 |
| EP2094669A2 (en) | 2006-12-18 | 2009-09-02 | Novartis AG | 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors |
| RU2009139811A (ru) | 2007-03-29 | 2011-05-10 | Новартис АГ (CH) | Гетероциклические спиросоединения |
| HK1201455A1 (en) | 2012-01-27 | 2015-09-04 | Gilead Sciences Inc | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| JOP20190086A1 (ar) * | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| WO2019241311A1 (en) * | 2018-06-11 | 2019-12-19 | Northeastern University | Selective ligands for modulation of girk channels |
| KR20230022829A (ko) | 2020-03-03 | 2023-02-16 | 트웬티에잇-세븐, 인크. | Rna 결합 단백질 또는 rna 변형 단백질을 표적으로 하는 화합물 |
| WO2022074567A1 (en) | 2020-10-06 | 2022-04-14 | Novartis Ag | Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia |
-
2022
- 2022-11-16 AR ARP220103160A patent/AR127698A1/es unknown
- 2022-11-17 UY UY0001040025A patent/UY40025A/es unknown
- 2022-11-21 WO PCT/IB2022/061218 patent/WO2023094965A1/en not_active Ceased
- 2022-11-21 AU AU2022396087A patent/AU2022396087A1/en active Pending
- 2022-11-21 CR CR20240216A patent/CR20240216A/es unknown
- 2022-11-21 RS RS20251242A patent/RS67492B9/sr unknown
- 2022-11-21 MA MA67325A patent/MA67325B1/fr unknown
- 2022-11-21 KR KR1020247020200A patent/KR20240110040A/ko active Pending
- 2022-11-21 CA CA3235682A patent/CA3235682A1/en active Pending
- 2022-11-21 DK DK22817365.4T patent/DK4436662T3/da active
- 2022-11-21 LT LTEPPCT/IB2022/061218T patent/LT4436662T/lt unknown
- 2022-11-21 JP JP2024529834A patent/JP7826477B2/ja active Active
- 2022-11-21 IL IL312689A patent/IL312689A/en unknown
- 2022-11-21 TW TW111144406A patent/TW202329949A/zh unknown
- 2022-11-21 MX MX2024006176A patent/MX2024006176A/es unknown
- 2022-11-21 PE PE2024001128A patent/PE20241328A1/es unknown
- 2022-11-21 EP EP22817365.4A patent/EP4436662B1/en active Active
- 2022-11-21 PT PT228173654T patent/PT4436662T/pt unknown
- 2022-11-21 FI FIEP22817365.4T patent/FI4436662T3/fi active
- 2022-11-21 HR HRP20251558TT patent/HRP20251558T1/hr unknown
- 2022-11-21 US US18/057,505 patent/US12084442B2/en active Active
- 2022-11-21 PL PL22817365.4T patent/PL4436662T3/pl unknown
- 2022-11-21 EP EP25202417.9A patent/EP4656240A1/en active Pending
- 2022-11-21 CN CN202280077045.1A patent/CN118382623A/zh active Pending
- 2022-11-21 ES ES22817365T patent/ES3054973T3/es active Active
-
2024
- 2024-05-20 DO DO2024000096A patent/DOP2024000096A/es unknown
- 2024-05-20 CL CL2024001524A patent/CL2024001524A1/es unknown
- 2024-05-21 CO CONC2024/0006398A patent/CO2024006398A2/es unknown
- 2024-05-21 EC ECSENADI202438829A patent/ECSP24038829A/es unknown
- 2024-05-23 JO JOJO/P/2024/0119A patent/JOP20240119A1/ar unknown
- 2024-08-07 US US18/797,142 patent/US20250214989A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001738A1 (es) | Inhibidores de prmt5 | |
| DOP2022000117A (es) | Inhibidores de kras g12c | |
| PY1996328A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| PY1932509A (es) | Inhibidores de cinasa dependientes de ciclina | |
| CO2024012743A2 (es) | Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| CL2024000067A1 (es) | Compuestos antivirales | |
| HN2002000067A (es) | Inhibidores de la rho - quinasa. | |
| CO2020014677A2 (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| CO2025011377A2 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| PY2018921A (es) | Agentes antiproliferativos para el tratamiento de pah | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| EA202192760A1 (ru) | Трициклические соединения | |
| MX2025002817A (es) | Compuestos para el tratamiento del cancer | |
| CO2023006912A2 (es) | Nuevos derivados de indazol acetileno | |
| MX2024012967A (es) | Derivados de piridina para el tratamiento de los trastornos psiquiatricos | |
| CO2024006398A2 (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| CU24543B1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| AR131945A1 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| UY39466A (es) | Compuestos y composiciones para el tratamiento de la criptosporidiosis | |
| CL2025002035A1 (es) | Compuestos moduladores de receptores de dopamina d3/d2 | |
| CR20250037A (es) | Inhibidores de cinasa dependientes de ciclina (divisional 2020-0503) |